RECURRENT MUCOSAL MELANOMA
Clinical trials for RECURRENT MUCOSAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MUCOSAL MELANOMA trials appear
Sign up with your email to follow new studies for RECURRENT MUCOSAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to block rare Melanoma's return
Disease control OngoingThis study tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgical removal. About 100 adults with this rare cancer will receive either nivolumab alone or nivolumab plus cabozantinib. The goal is to see which…
Matched conditions: RECURRENT MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New hope for melanoma patients: could pembrolizumab outperform current treatments?
Disease control OngoingThis study compared pembrolizumab (Keytruda) to the usual treatments (high-dose interferon or ipilimumab) in over 1,300 people with high-risk melanoma that was surgically removed. The goal was to see if pembrolizumab could better prevent the cancer from coming back or spreading. …
Matched conditions: RECURRENT MUCOSAL MELANOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC